KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.

Liwen Li, Yujie Zhou, Chanjuan Deng, Jianlong Sheng, Daoquan Peng, Zhiyu Ling, Luya Wang, Cuilian Dai, Kai Huang, Qiufang Lian, Zaixin Yu, Haibo Yang, Yuying Hu, YuGang Dong, Nan Wang, Zhen Wang, Wei Zhang, Xuebin Han, Zhuhua Yao, Qiyun Liu, Yingzi Liang, Biao Xu, Ying Wang, Tingyan Zhong, Jiyan Chen

Cardiovasc Res 121(12) 1856-1864

PMID40911402
PMCID-
DOI10.1093/cvr/cvaf155
发表日期2025-09-05
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

AIMS: Heterozygous familial hypercholesterolaemia (HeFH) is a genetic disorder, characterized by high plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth. This study aimed to assess the efficacy and safety of recaticimab, a new humanized anti-PCSK9 antibody capable of reducing LDL-C levels in patients with poorly controlled HeFH. METHODS AND RESULTS: REMAIN-3 was a multicentre, randomized, double-blind, placebo-controlled Phase 3 study done at 25 sites in China. Patients with a genetic or clinical diagnosis of HeFH, who were on stable lipid-lowering therapy for ≥28 days, had fasting LDL-C ≥ 2.6 mmol/L (or ≥1.8 mmol/L for those with a history of atherosclerotic cardiovascular disease), and had fasting triglyceride ≤5.6 mmol/L, were randomly allocated in a 2:1 ratio to receive subcutaneous recaticimab at 150 mg or matching placebo every 4 weeks for 12 weeks. The primary endpoint was the percentage change in LDL-C from baseline to Week 12. Overall, 143 patients underwent randomization and received recaticimab (n = 95) or placebo (n = 48). At Week 12, the mean percentage change in LDL-C from baseline was -54.4% (95% CI, -57.9 to -50.8%) in the recaticimab group and -4.5% (95% CI, -9.4 to 0.3%) in the placebo group, with a treatment difference of -49.8% (95% CI, -55.8 to -43.9%; P < 0.0001). Recaticimab was superior to placebo in improving other lipid variables, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein a. Treatment-related adverse events (TRAEs) were comparable between groups (27.4% with recaticimab vs. 25.0% with placebo). The most common TRAEs occurring more frequently with recaticimab than placebo were injection site reaction (8.4% vs. 0%) and increased blood creatine phosphokinase (5.3% vs. 2.1%). CONCLUSION: Recaticimab significantly lowered the LDL-C level compared with placebo, with an acceptable safety profile, providing a new effective treatment option for patients with inadequately controlled HeFH. REGISTRATION: ClinicalTrials.gov Identifier: NCT04844125.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。